AROA APPOINTS MARK DUNWOODIE AS CHIEF FINANCIAL OFFICER

Highlights

- Mark Dunwoodie appointed Chief Financial Officer and Joint Company Secretary, effective 16 November 2026.
- More than 25 years of financial, strategic, and operational leadership experience.
- Joins AROA from NZX-listed Rakon Limited, where he served as Chief Financial Officer.
- Appointment supports an orderly transition from outgoing Chief Financial Officer James Agnew.

Aroa Biosurgery Limited (ASX: ARX, "AROA" or the "Company") is pleased to announce the appointment of Mark Dunwoodie as Chief Financial Officer and Joint Company Secretary, effective 16 November 2026**.**

Mark joins AROA from NZX-listed Rakon Limited, where he served as Chief Financial Officer and supported the company's growth strategy and organisational transformation.

He brings more than 25 years of financial, strategic, and operational leadership experience across listed companies, international financial services, and business advisory.

As Chief Financial Officer, Mark will work alongside CEO Brian Ward and the leadership team to support AROA's growth strategy as the Company continues to scale internationally, particularly in the United States.

The appointment follows a comprehensive recruitment process and supports an orderly transition from outgoing Chief Financial Officer James Agnew, who departs the company on 30 November, following release of AROA's half year financial results and investor roadshow.

AROA CEO Brian Ward said:

"We are pleased to welcome Mark to AROA. He has extensive experience leading finance functions in listed and international businesses, including through periods of growth and transformation. His financial discipline and strategic insight will be valuable as we continue to scale AROA.

I would also like to thank James for his significant contribution to AROA over the past 13 years. The financial, governance and operational foundations he has helped establish have positioned the Company well for its next phase of growth. We wish him every success."

<ENDS>

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

AROA BIOSURGERY LIMITED
ARBN 638 867 473 NZCN 1980577
64 Richard Pearse Drive, Auckland 2022, New Zealand
AROA.COM

Contact

investor@aroa.com

About AROA™
Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for every*body*'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix bioscaffold derived from ovine (sheep) forestomach. Over 7.5 million AROA devices have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELABio, Inc. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroa.com